Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AKRINOL vs DEHYDRATED ALCOHOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Not available; likely a combination product with antihistaminic and sympathomimetic actions.
Dehydrated alcohol (ethanol) causes tissue necrosis by protein denaturation and cellular dehydration, leading to vascular thrombosis and ischemic infarction. It ablates nerve tissue by extracting lipids and precipitating proteins.
Allergic rhinitis,Nasal congestion
FDA-approved for adjunctive therapy in the treatment of cystic thyroid nodules,Off-label: Neurolysis for celiac plexus block in pancreatic cancer pain,Off-label: Ablation of hepatocellular carcinoma,Off-label: Sclerotherapy for esophageal varices
Adults: 100 mg orally twice daily.
Intravenous administration: 0.1-1 m L of sterile dehydrated alcohol (100% ethanol) injected directly into cystic lesions or tumors under imaging guidance. Maximum volume per injection: 1 m L, repeated up to 3 times per session depending on lesion size.
3-4 hours (prolonged to 8-12 hours in renal impairment; no dose adjustment typically needed unless Cr Cl <30 m L/min).
2-4 hours in most individuals at zero-order kinetics; terminal half-life is concentration-dependent due to saturation of alcohol dehydrogenase. Clinically, elimination rate is constant at 15-20 mg/d L/hour in non-tolerant individuals.
Not available; components may be metabolized via hepatic CYP enzymes.
Primarily hepatic via alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH); minor metabolism via CYP2E1 at high concentrations.
Primarily renal (80-90% as unchanged drug via glomerular filtration and tubular secretion); minor biliary/fecal (5-10%).
Ethanol is primarily eliminated by hepatic metabolism (90-98%) via alcohol dehydrogenase and aldehyde dehydrogenase, with 2-10% excreted unchanged in urine, breath, and sweat. Renal elimination is minor and variable.
99.5% (primarily to albumin; also to α1-acid glycoprotein).
Negligible (<5%); no specific binding proteins.
0.10-0.17 L/kg (low, indicating limited extravascular distribution; primarily in central compartment).
0.5-0.7 L/kg, approximating total body water. Higher in females due to lower lean body mass.
Oral: 3-5% (extensive first-pass metabolism); IV: 100%.
Oral: ~80-100% due to rapid absorption from stomach and small intestine; IV: 100%.
GFR 30-59 m L/min: 50 mg daily; GFR <30 m L/min: 50 mg every other day.
No dosage adjustment required for renal impairment.
Child-Pugh A: 100 mg twice daily; Child-Pugh B: 50 mg twice daily; Child-Pugh C: 50 mg daily.
No specific Child-Pugh-based adjustments; use with caution in severe hepatic dysfunction due to potential accumulation.
Children (1-12 years): 2 mg/kg orally twice daily, max 100 mg/dose.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
Adults >65 years: initiate at 50 mg twice daily, titrate to 100 mg twice daily as tolerated.
No specific dose adjustment; use with caution due to age-related comorbidities and potential for increased sensitivity.
None
No FDA boxed warning exists for dehydrated alcohol. However, it should only be administered by physicians experienced in injection techniques for specific indications due to risk of tissue necrosis and nerve damage.
Use with caution in patients with hypertension,Avoid in patients with severe coronary artery disease
Risk of tissue necrosis and sloughing if extravasation occurs,Neurological injury if injected near nerves (e.g., peripheral nerve damage, paralysis),Hypotension and bradycardia during celiac plexus block,Alcohol intoxication and CNS depression if absorbed systemically,Use with caution in patients with liver disease or diabetes mellitus
Hypersensitivity to any component,Severe hypertension,Concomitant use with MAO inhibitors
Hypersensitivity to ethanol or any component of the formulation,Acute infection at the injection site,Uncorrectable coagulation abnormalities,Pregnancy (relative contraindication due to fetal alcohol spectrum disorders)
No known food interactions with topical naftifine. No dietary restrictions required.
No specific food interactions. However, avoid alcohol consumption for 24 hours post-procedure due to risk of additive CNS depression.
FDA Pregnancy Category D. First trimester: risk of CNS defects and spontaneous abortion. Second/third trimester: risk of premature closure of ductus arteriosus, oligohydramnios, renal dysfunction, necrotizing enterocolitis, periventricular hemorrhage, and pulmonary hypertension.
First trimester: Data limited; alcohol is a known teratogen causing fetal alcohol spectrum disorders. Increased risk of congenital anomalies (e.g., heart defects, microcephaly) with high systemic exposure. Second trimester: Continued risk for growth restriction and neurodevelopmental abnormalities. Third trimester: Risk of growth retardation, preterm birth, and neurobehavioral deficits. Avoid systemic use; local injection for nerve block or ablation has minimal systemic absorption but caution advised.
Contraindicated during breastfeeding. M/P ratio not determined due to contraindication. Excreted into breast milk; potential for serious adverse effects in infant.
Alcohol is excreted into breast milk; M/P ratio approximately 1.0. Chronic ingestion can impair infant motor development. Dehydrated alcohol for therapeutic injection likely results in negligible systemic levels; however, avoid breastfeeding immediately after procedure. Advise discarding milk for 2-3 hours post-procedure.
No established safe dose. Generally contraindicated during pregnancy. If used, lowest effective dose and shortest duration. Avoid after 20 weeks gestation.
No dose adjustment needed for localized injection; pharmacokinetics of ethanol unchanged in pregnancy. Avoid use as systemic agent; use alternative if possible.
AKRINOL is a topical antifungal (naftifine) that inhibits squalene epoxidase, effective against dermatophytes. Apply once daily for 2-4 weeks. Avoid occlusive dressings. Monitor for local irritation or allergic contact dermatitis.
Absolute ethanol (dehydrated alcohol) is used for neurolysis in celiac plexus block for pancreatic cancer pain and for ablation of certain soft tissue lesions. Administer slowly to avoid local toxicity. Inadvertent intravascular injection can cause immediate pain and tissue necrosis. Use ultrasound or CT guidance for accurate placement. Monitor for hypotension, pain, and transient alcohol intoxication. Contraindicated in patients with bleeding disorders or local infection.
Apply a thin layer to the affected area once daily, usually for 2 to 4 weeks.,Wash hands before and after application unless treating the hands.,Do not cover the treated area with bandages or wraps unless directed.,Avoid contact with eyes, nose, mouth, or broken skin. If contact occurs, rinse with water.,Notify your doctor if condition worsens, does not improve within 4 weeks, or if severe irritation or allergic reaction develops.
You may feel a temporary burning sensation at the injection site.,This medication is used to block pain signals from certain nerves.,Avoid alcohol consumption for 24 hours after the procedure to prevent additive effects.,Report any severe pain, bleeding, or signs of infection to your healthcare provider.,You may experience temporary dizziness or lightheadedness after the injection.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AKRINOL vs DEHYDRATED ALCOHOL, answered by our medical review team.
AKRINOL is a Topical Retinoid that works by Not available; likely a combination product with antihistaminic and sympathomimetic actions.. DEHYDRATED ALCOHOL is a Sclerosing agent that works by Dehydrated alcohol (ethanol) causes tissue necrosis by protein denaturation and cellular dehydration, leading to vascular thrombosis and ischemic infarction. It ablates nerve tissue by extracting lipids and precipitating proteins.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AKRINOL and DEHYDRATED ALCOHOL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AKRINOL is: Adults: 100 mg orally twice daily.. The standard adult dose of DEHYDRATED ALCOHOL is: Intravenous administration: 0.1-1 m L of sterile dehydrated alcohol (100% ethanol) injected directly into cystic lesions or tumors under imaging guidance. Maximum volume per injection: 1 m L, repeated up to 3 times per session depending on lesion size.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AKRINOL and DEHYDRATED ALCOHOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AKRINOL is classified as Category C. FDA Pregnancy Category D. First trimester: risk of CNS defects and spontaneous abortion. Second/third trimester: risk of premature closure of ductus arteriosus, oligohydramnios, re. DEHYDRATED ALCOHOL is classified as Category C. First trimester: Data limited; alcohol is a known teratogen causing fetal alcohol spectrum disorders. Increased risk of congenital anomalies (e.g., heart defects, microcephaly) wit. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.